{
  "drugDiseasePairs": [
    {
      "id": "1",
      "drugName": "Metformin",
      "drugNdcCode": "0093-1115-01",
      "diseaseName": "Alzheimer's Disease",
      "diseaseOntologyTerm": "MONDO:0004975",
      "biologicalSuitability": 7.2,
      "unmetMedicalNeed": 9.1,
      "economicSuitability": 6.8,
      "marketSize": 8.5,
      "competitiveAdvantage": 5.9,
      "regulatoryFeasibility": 7.3,
      "clinicalRisk": 4.2,
      "compositePrioritizationScore": 7.1,
      "narrative": "Metformin, a widely used diabetes medication, shows promising neuroprotective effects through AMPK activation and reduction of neuroinflammation. Clinical studies suggest potential benefits in cognitive decline prevention, making it an attractive repurposing candidate for Alzheimer's disease."
    },
    {
      "id": "2",
      "drugName": "Sildenafil",
      "drugNdcCode": "0069-4200-66",
      "diseaseName": "Pulmonary Hypertension",
      "diseaseOntologyTerm": "MONDO:0005149",
      "biologicalSuitability": 8.9,
      "unmetMedicalNeed": 8.7,
      "economicSuitability": 7.1,
      "marketSize": 6.3,
      "competitiveAdvantage": 8.2,
      "regulatoryFeasibility": 9.1,
      "clinicalRisk": 3.5,
      "compositePrioritizationScore": 7.8,
      "narrative": "Originally developed for erectile dysfunction, sildenafil's mechanism of action through PDE-5 inhibition makes it highly effective for pulmonary arterial hypertension. This represents one of the most successful drug repurposing examples, with established safety profile and clear therapeutic benefit."
    },
    {
      "id": "3",
      "drugName": "Aspirin",
      "drugNdcCode": "0536-1010-01",
      "diseaseName": "Colorectal Cancer Prevention",
      "diseaseOntologyTerm": "MONDO:0005575",
      "biologicalSuitability": 6.8,
      "unmetMedicalNeed": 7.9,
      "economicSuitability": 9.2,
      "marketSize": 9.5,
      "competitiveAdvantage": 6.1,
      "regulatoryFeasibility": 6.8,
      "clinicalRisk": 5.3,
      "compositePrioritizationScore": 7.3,
      "narrative": "Low-dose aspirin shows significant potential in colorectal cancer prevention through COX-2 inhibition and anti-inflammatory pathways. Large epidemiological studies support its chemopreventive effects, though optimal dosing and patient selection strategies require further refinement."
    },
    {
      "id": "4",
      "drugName": "Thalidomide",
      "drugNdcCode": "59572-102-00",
      "diseaseName": "Multiple Myeloma",
      "diseaseOntologyTerm": "MONDO:0009693",
      "biologicalSuitability": 8.1,
      "unmetMedicalNeed": 9.3,
      "economicSuitability": 5.4,
      "marketSize": 7.2,
      "competitiveAdvantage": 7.8,
      "regulatoryFeasibility": 4.9,
      "clinicalRisk": 7.6,
      "compositePrioritizationScore": 6.7,
      "narrative": "Despite its tragic history, thalidomide's immunomodulatory and anti-angiogenic properties have proven invaluable in multiple myeloma treatment. Its complex mechanism involving cereblon modulation has opened new therapeutic avenues, though careful monitoring for serious adverse effects remains critical."
    },
    {
      "id": "5",
      "drugName": "Topiramate",
      "drugNdcCode": "0555-0960-02",
      "diseaseName": "Obesity",
      "diseaseOntologyTerm": "MONDO:0011122",
      "biologicalSuitability": 5.7,
      "unmetMedicalNeed": 8.8,
      "economicSuitability": 6.9,
      "marketSize": 9.1,
      "competitiveAdvantage": 4.8,
      "regulatoryFeasibility": 6.2,
      "clinicalRisk": 6.1,
      "compositePrioritizationScore": 6.5,
      "narrative": "Originally an antiepileptic drug, topiramate's appetite suppressant effects through multiple neurotransmitter pathways make it a candidate for obesity treatment. While weight loss benefits are documented, cognitive side effects and limited long-term data present challenges for widespread adoption."
    }
  ]
}
